Lymphoid Malignancies Think Tank Therapeutic Opportunities in Lymphomas
|
|
- Tracy May
- 5 years ago
- Views:
Transcription
1 Lymphoid Malignancies Think Tank Therapeutic Opportunities in Lymphomas Wyndham H. Wilson, MD, PhD Bethesda, Maryland
2 Distribution of Lymphoma Subtypes % of Total Cases Diffuse La rge B-ce ll Follicular Lymphoma Ma rgina l zone B-ce ll lymphoma, MALT 6.0% MCL DLBCL 30.6% Periphera l T-cell lymphomas CLL/SLL 6.7% 7.0% PTL 7.6% MZL FCC 22.1% Mantle Cell Lymphoma Mediastinal Large B-cell Lymphoma Ana pla s tic La rge Ce ll Lymphoma/T-null
3 Historical Outcome of Lymphoma Subtypes Aggressive B Cell Lymphomas Diffuse Large B-cell Lymphoma (DLBCL) Mantle cell lymphoma (MCL) Indolent B Cell Lymphomas Follicular center cell (FCC)
4 Aggressive Lymphoma (DLBCL) 100 Percent Cure 33% 20 P = 0.35 Fisher Intergroup Trial (PFS) Years After Randomization CHOP m-bacod ProMACE-CytaBOM MACOP-B Patients at Risk Relapses or Deaths 3-Year Estimate % 46% 46% 41%
5 Mantle Cell Lymphoma Median survival 3 years Fisher et al. Blood 85:1075; 1995
6 Indolent Lymphoma (FCC) Median Survival 10 years
7 Strategies in DLBCL Empiric Targeted Identify targets and reagents Clinically assess and validate Clinical trials Evaluate molecular mechanisms of treatment failure Build molecular prognostic models Assess tumor biology treatment regimens Rationally develop new-generation treatments
8 Rituximab: An Anti-CD20 MAb An Empiric Success Chimeric murine/human MAb Variable light- and heavychain regions from murine anti-cd20 antibody Linked to human IgGκ constant regions
9 LNH-98.5 Phase III CHOP v CHOP plus Rituximab Cyclophosphamide 750 mg/m² Doxorubicine 50 mg/m² Vincristine 1.4 mg/m² Prednisone 40 mg/m²/d x 5 d 3 weeks 8 cycles CHOP Rituximab 375 mg/m²
10 GELA study Median follow-up 5 y 1.0 Event-Free Survival 1.0 Survival R-CHOP CHOP % 0.4 R-CHOP CHOP p = p = Years Years
11 Diffuse Large B-Cell Lymphoma Molecular Prognostic Model of CHOP Failure
12 Proliferation Signature Percent Survival Low proliferation High proliferation Rosenwald et al NEJM 346:1937, 2002 Years
13 Ki-67 Analysis of Tumor Proliferation Survival Outcome With CHOP bolus Ki-67 < 80% Median survival 39 months Ki-67 > 80% Median survival 7 months Blood 83:1460, 1994
14 Hypothesis Drug schedule increases tumor drug sensitivity Doxorubicin 7 day 3 hr Schedule dependent drugs Doxorubicin Etoposide Vincristine SW6200
15 Hypothesis Drug schedule impacts drug sensitivity and mechanism Cell cycle apoptotic threshold Cell cycle Drug targets
16 Tumor Proliferation Survival Outcome CHOP v DA-EPOCH CHOP Bolus DA-EPOCH Infusional Survival Probability Low High P = High Low P = 0.11 Years on study Years on study High Proliferation (Ki67 > 80%) Low Proliferation (Ki67 < 80%)
17 DA-EPOCH-R Infusional Survival Outcomes PFS and OS: 83% Percent Untreated DLBCL (n=90) 20 Median Follow-up: 3 years Months on Study 72
18 Diffuse Large B-Cell Lymphoma Biology of CHOP Failure
19 Effect of GCB v ABC Subtypes on Outcome CHOP Bolus Treatment
20 GCB v ABC DLBCL BCL-2 impacts survival 25% v. 8 yrs (P < 0.001) CHOP-based (Blood 83:1460, 1994) BCL-2 Expression Associated with ABC ABC v GCB (p = 0.003)
21 Effect of Rituximab on BCL-2 BCL-2 Expression CD20+ CD20- BCL-2 Expression Clin Cancer Res 2001 Mar;7(3):709-23
22 Effect of Rituximab in BCL-2+ Tumors NCI EPOCH v EPOCH-R
23 Effect of Rituximab in BCL-2+ Tumors GELA CHOP v R-CHOP % survival CHOP OS, P=0.05 bcl2 (45) bcl2 + (92) Years % survival R-CHOP OS, P=0.71 bcl2 (54) bcl2 + (101) Years
24 GCB v ABC Survival Outcome EPOCH-R Infusional Survival (%) ABC: 69% GCB: 89% p 2 = Median Follow-up: 36 months Months on Study 72
25 CALGB Phase III Randomized Study of R-CHOP v. DA-EPOCH-R with Microarray ARM A: R-CHOP Treatment completed C1 C2 C3 C4 C5 C6 C7 C8 Randomization Tumor Biopsy Blood Samples Stage Stage Stage C1 C2 C3 C4 C5 C6 C7 C8 Repeat Blood Samples at Staging Proteomics/Pharmacogenomics ARM B: DA-EPOCH-R Treatment completed if no change C5 to C7 staging Treatment completed if change C5 to C7 staging Time Line (weeks)
26 Targeting NF- κb in the ABC Subtype
27 Bortezomib and NF-κB Bortezomib inhibits release of NF-κB dimers through inhibiting proteosome clearance of IκB Activation of the NF-kB Signaling Pathway
28 Phase I/II Study of Bortezomib + EPOCH Part A Bortezomib single agent Part B DA-EPOCH + Bortezomib days 1 and 4 Bortezomib Dose Escalated: Level I 0.5 mg/m 2 Level II 1.0 mg/m 2 Level III 1.5 mg/m 2 Level IV 1.7 mg/m 2
29 Phase I/II Study of Bortezomib + EPOCH Part A Bortezomib single agent Part B DA-EPOCH + Bortezomib days 1 and 4 Bortezomib Dose Escalated: Level I 0.5 mg/m 2 Level II 1.0 mg/m 2 Level III 1.5 mg/m 2 Level IV 1.7 mg/m 2 ORR 6% (1/16) 23% (6/26)
30 Strategies in Mantle Cell Lymphoma Chemotherapy sensitive but persistent MRD Characterized by cell-cycle dysregulation Proliferative Signal DNA DS Breaks Cyclin D1 / cdk4 p16 ATM 50%? Sequestration Rb E2F p14 ARF Methylated promoter mdm2 p53 More common in blastic p27 Cyclin E/cdk2 p21 BAX Deleted PROLIFERATION Deleted APOPTOSIS Courtesy O. O Connor
31 Tumor Proliferation
32 Tumor Proliferation Predicts Outcome
33 PFS Not Dependent on Proliferation Signature EPOCH-R Infusional
34 Immune Eradication of MRD Idiotype Vaccine Protocol Schema LN Bx EPOCH-R Begins EPOCH-R Ends Id/KLH + GM-CSF s.c. Weeks n = 26 EPOCH-R 6 cycles EPOCH-R Rituximab iv Day 1 Continuous infusion Etoposide, Doxorubicin, Vincristine Days 1-5 Cyclophosphamide iv Day 5 Prednisone po Days 1-5 Dose Adjustment Id-KLH+GM-CSF 0.5 mg autologous Id mg KLH µg/m 2 GM-CSF
35 PFS and OS With Idiotype Vaccine Progression-Free Survival Overall Survival OS 4 years Percent Percent Median follow-up 46 months Median PFS 22 months PFS 4 years 20 Median follow-up 46 months Years on Study Years on Study 3 4 5
36 Inhibition of Cell-Cycle Targets Proteosome inhibitor Known Proteosome Substrates CLASS Cyclins Tumor Suppressor Oncogenes Inhibitory Proteins Enzymes PROTEIN Cylins A, B, D E Cdk Inhibitors P53 (p21 and p27) C-fos/c-jun C-myc N-myc IkB P130 / bcl-2 Cdc25 phosphatase Tyrosine aminotransferase PROTEIN FUNCTION Cell cycle Cyclin regulation Transcription factor Transcription factor Transcription factor Transcription factor Inhibitor of NF-kB Inhibitor of E2F-1 CDK1/cyclin B phosphatase Tyrosine metabolism
37 Summary of Recent Data Mantle Cell Lymphoma Study N CR/CRu PR ORR O Connor et al (MSKCC) 26 3/2 (19%) 9 (38%) 54% (ASH 2004) Strauss et al (St. Barts) 18 1 (6%) 6 (33%) 39% (ASH 2004) Belch et al (NCIC) 28 1 (4%) 12 (43%) 46% (ASH 2004) Goy et al (MDACC) 29 6 (21%) 6 (21%) 41% (JCO 2005, ahead of print Dec 21, 2004)
38 Summary of Recent Data Indolent Lymphoma Study N CR/CRu PR ORR O Connor (MSKCC) (ASH 2004) Follicular 15 1/1 (13%) 7 (47%) 60% SLL (20%) 20% MZL (50%) 50% Strauss et al (St. Barts)* (ASH 2004) Follicular (18%) 18% Goy et al (MDACC) (JCO 2005, ahead of print Dec 21, 2004) Follicular NA* 0/1 - NA* SLL NA* 1/0 - NA*
39 Inhibition of mtor Growth Factor Cell Membrane PI3k Cell Growth PIP-3 AKT PTEN CCI-779/ RAD001 Regulate Translation of cell cycle regulatory proteins P P Courtesy of O Connor mtor P70 S6K1 4E-BP1
40 Phase II Study CCI-779 (Temsirolimus) Relapsed Mantle Cell Lymphoma Arm A: N = 34 Response: ORR: 38% CR 1 PR 12 PFS Median (range) 6.5 ( ) Arm B: N= 13 Toxicity (Grade 3): Thrombocytopenia: 63% Neutropenia: 23% Response: ORR: 54% CR 1 PR 6 Delayed cycles PFS too early 6/7 responses 2 months Toxicity (Grade 3): Thrombocytopenia: 23% Neutropenia: 23% Lower thrombocytopenia Witzig, T, Geyer S, Ghobrial I, et al. Proceed ASCO # 129, 2005
41 Inhibition of Histone Deacetylation
42 Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) Histone Deacetylase (HDAC) Inhibitor Inhibition of Histone H3 Deacetylation by SAHA in PBMC Kelly WK et al. Clin Cancer Res 9:3578, 2003
43 Cyclin-Dependent Kinase Inhibitor Flavopiridol Derived by synthesis from Dysoxylum binectariferum, plant indigenous to India CDK inhibitor: Directly binds to the ATP binding site at nanomolar concentrations (e.g. cyclin D1) Kaur G, et al., JNCI, 1992, 84: 1736, 92.
44 Flavopiridol in Mantle Cell Lymphoma No Prior Therapy Prior Therapy Total # Pts. (n=28) Duration Range Complete Remission Partial Remission Stable Disease POD Overall Response 2 / 11 [18%] 1 / 17 [6%] 24% - - Kouroukis et al., 2003
45 Immunomodulatory Drugs (IMiD) Inhibition of TNF-α Production in Monocytes Mediator of inflammation Pro-angiogenic Induces cellular proliferation T-cell Costimulatory Activity Increased activation/proliferation Increased cytokine production (IL-2, IL-12 and TNF-α) Shift toward Th1 (helper) phenotype Enhance NK and LAK activity
46 Survival Outcomes in Mantle Cell Lymphoma Thalidomide and Rituximab Overall Survival PFS; Median 20.4 months Prior Therapy PFS Thalidomide + Rituximab Kaufmann, H. et al. Blood 2004;104:
47 Lenalidomide (CC-5013, Revlimid ) New-Generation ImiD O N O H N O O N O H N O O Thalidomide NH 2 Lenalidomide Courtesy of O Connor Bartlett JB et al. Nat Rev Cancer. 2004;4:314 Stirling D. Semin Oncol. 2001;28:602
48 Protocol Construction Opportunity window For activity biomarkers Targeted Agent Obtain pre and post Bx after one cycle Maximize cytotoxicity and therapeutic index Neoadjuvant Eradicate RTC Targeted Agent Chemotherapy + Targeted agent Post-CT+ TA Randomize Observation
49 Protocol Construction Biomarkers Microarray Proteomics Bortezomib Obtain pre and post Bx after one cycle Endpoints EFS OS MRD Correlate bortezomib biomarkers with outcome MRD Detection Bortezomib X 18 months DA-EPOCH-R + Bortezomib Post-CT+ TA Randomize Observation
50 Acknowledgements Clinical Studies John Janik, Kieron Dunleavy Nicole Grant, Therese White Martin Gutierrez, Upendra Hegde Bruce Chabner, Michael Grossbard Metabolism Branch Louis Staudt Andreas Rosenwald Adrian Wiestner Pharmacology Studies (Pediatric Branch) Frank Balis, Diane Cole Elizabeth Lowe Laboratory of Pathology Stefania Pittaluga Elaine Jaffe Mark Raffeld, Mary-Alice Stetler-Stevenson
Treatment Landscape in R/R DLBCL Novel Targets and Strategies. Wyndham H. Wilson, M.D., Ph.D. Senior Investigator
Treatment Landscape in R/R DLBCL Novel Targets and Strategies Wyndham H. Wilson, M.D., Ph.D. Senior Investigator Gene-expression profiling of DLBCL subtypes Roschewski, M. et al. (2013) Nat. Rev. Clin.
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationManaging patients with relapsed follicular lymphoma. Case
Managing patients with relapsed follicular lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Professor of Medicine Associate Director, Weill Cornell
More informationHave we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES!
Have we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES! Christopher Flowers, MD, MSc Associate Professor Director, Lymphoma Program Department of Hematology and Oncology Emory School of Medicine
More informationDr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009
Treatment of DLBCL Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009 Non-hodgkin lymphomas DLBCL Most common NHL subtype throughout the world many other types of lymphoma with striking geographic variations
More informationESMO DOUBLE-HIT LYMPHOMAS
ESMO DOUBLE-HIT LYMPHOMAS Professor Dr. med. Georg Lenz Director Department of Hematology and Oncology Universitätsklinikum Münster, Germany OVERVIEW Definition of double-hit lymphomas Introduction in
More informationMantle Cell Lymphoma
Mantle Cell Lymphoma Clinical Case A 56 year-old woman complains of pain and fullness in the left superior abdominal quadrant for the last 8 months. She has lost 25 kg, and lately has had night sweats.
More informationAggressive B and T cell lymphomas: Treatment paradigms in 2018
Aggressive B and T cell lymphomas: Treatment paradigms in 2018 John P. Leonard M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Associate
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationUpdates in the Treatment of Non-Hodgkin Lymphoma: ASH Topics
Updates in the Treatment of Non-Hodgkin Lymphoma: ASH 2008 Joseph Tuscano, M.D. UC Davis Cancer Center 1 Topics Mantle Cell Lymphoma What is the standard of care for younger patients? (abstracts 581, 769,
More informationDiffuse Large B-Cell Lymphoma Front line Therapy John P. Leonard, MD Weill Cornell Medicine New York, New York USA
Diffuse Large B-Cell Lymphoma Front line Therapy John P. Leonard, MD Weill Cornell Medicine New York, New York USA Disclosures Consulting advice: Hospira, Bayer, Juno Therapeutics, Teva, Oncotracker, Gilead
More informationNuove opportunità di cura. Stefano Sacchi, Modena
Nuove opportunità di cura Stefano Sacchi, Modena Antiangiogenesis therapies The goal is to target the blood supply that feeds tumors. Vorinostat (suberoylanilide hydroxamic acid - SAHA) TOPIC SEARCH:
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationAggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV
Aggressive lymphomas ASH 2015 Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV CHOP 1992 2002 R-CHOP For DLBCL High dose chemo With PBSCT Aggressive lymphomas 1.DLBCL 2.Primary Mediastinal Lymphoma 3.CNS
More informationeastern cooperative oncology group Michael Williams, Fangxin Hong, Brad Kahl, Randy Gascoyne, Lynne Wagner, John Krauss, Sandra Horning
Results of E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Indolent B-Cell Lymphoma Michael Williams, Fangxin Hong, Brad Kahl, Randy
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationOSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD
OSCO/OU ASH-SABC Review Lymphoma Update Mohamad Cherry, MD Outline Diffuse Large B Cell Lymphoma Double Hit Lymphoma Follicular and Indolent B Cell Lymphomas Mantle Cell Lymphoma T Cell Lymphoma Hodgkin
More informationTreatment Nodal Marginal Zone Lymphoma
Workshop : Indolent lymphomas Treatment Nodal Marginal Zone Lymphoma Catherine Thieblemont Hôpital Saint-Louis, Paris - France Bologna 16th, 2017 Ø No standardized treatment Ø Similarly treated as FL Treatment
More informationUpdate: New Treatment Modalities
ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant
More informationMantle cell lymphoma An update on management
Mantle cell lymphoma An update on management Dr Kim Linton Consultant Medical Oncologist The Christie NHS Foundation Trust 6 th October 2016 This educational meeting is organised and sponsored by Janssen-Cilag
More informationThe treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona
The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationConflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center
What Is Personalized Medicine For Patients With Lymphoma? Conflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center DISCLOSURE I have no potential
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationMantle Cell Lymphoma: Update in Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency
Mantle Cell Lymphoma: Update in 2015 Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency Disclosures Research funding: Roche provides research funding to support the Centre for Lymphoid Cancer
More information12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
More informationHIV ASSOCIATED LYMPHOMA. Dr N Rapiti
HIV ASSOCIATED LYMPHOMA Dr N Rapiti HIV ASSOCIATED LYMPHOMA: OVERVIEW Classification Pathogenesis Prognosis cart Chemotherapy/Radiotherapy/SCT Supportive CASE 40 yr old male, Mr BM, p/w Symptomatic anemia
More informationWho should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable
More informationLymphoma update: turning biology into cures. Peter Johnson
Lymphoma update: turning biology into cures Peter Johnson Selected highlights of recent research 1. Using FDG-PET to modify treatment and avoid long term toxicity in Hodgkin lymphoma 2. Understanding how
More informationThe case for maintenance rituximab in FL
New-York, October 23 rd 2015 The case for maintenance rituximab in FL Pr. Gilles SALLES For FL patients, progression-free survival still needs to be improved Median R-CHVP-I 66 months P
More informationNCCTG Status Report for Study N0275 May 2011
NCCTG Status Report for Study N0275 May 2011 Phase II Trial Evaluating Resection Followed by Adjuvant Radiation Therapy (RT) for Patients with Desmoplastic Melanoma Primary Goals 1. Assess the recurrence
More informationLymphomas in Prof Paul Ruff Division of Medical Oncology
Lymphomas in 2010 Prof Paul Ruff Division of Medical Oncology Most Common Lymphomas: ~90% B-cell and ~10% T-cell T lymphoblastic: 2% Marginal zone, nodal: 2% Other: 9% Burkitt: 2% Anaplastic large cell:
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe founded in 1985 Comparison of Two Consecutive Study Generations of the GLSG Overall Survival Follicular Lymphomas Questions for the Next Steps of
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationHow I treat High-risk follicular lymphoma
How I treat High-risk follicular lymphoma Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona 1) median OS raised from 10 to 18 y 2) advanced FL remains uncurable Stanford, n = 1334
More informationNational Horizon Scanning Centre. Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory. January 2008
Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory January 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationNON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and
More informationMantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents
Mantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center Friday March 16, 2018: 11:15-11:30
More informationHead and Neck: DLBCL
Head and Neck: DLBCL Nikhil G. Thaker Chelsea C. Pinnix Valerie K. Reed Bouthaina S. Dabaja Department of Radiation Oncology MD Anderson Cancer Center Case 60 yo male Presented with right cervical LAD
More informationNCCN Non Hodgkin s Lymphomas Guidelines V Update Meeting 06/14/12 and 06/15/12
NCCN Non Hodgkin s Lymphomas Guidelines V.1.213 Update Meeting 6/14/12 and 6/15/12 Guidelines Page and Request Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Panel Discussion References
More informationNovel treatment options for Waldenstrom Macroglobulinemia
Novel treatment options for Waldenstrom Macroglobulinemia Irene Ghobrial, MD Associate Professor of Medicine Harvard Medical School Dana Farber Cancer Institute Boston, MA Ghobrial et al, Lancet Oncol
More informationLymphoma Update 2018
Lymphoma Update 2018 Sonali M. Smith, MD Elwood V. Jensen Professor of Medicine Section of Hematology/Oncology Director, Lymphoma Program The University of Chicago April 18, 2018 Disclosure Information
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationState of the Art Treatment for Relapsed Mantle Cell Lymphoma
Winship Cancer Institute of Emory University State of the Art Treatment for Relapsed Mantle Cell Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor, BMT Program Emory University- Winship Cancer Institute
More informationGazyva (obinutuzumab)
STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination
More information2012 by American Society of Hematology
2012 by American Society of Hematology Common Types of HIV-Associated Lymphomas DLBCL includes primary CNS lymphoma (PCNSL) Burkitt Lymphoma HIV-positive patients have a 60-200 fold increased incidence
More informationDA-EPOCH-R (Etoposide/Inpatient)
DA- (Etoposide/Inp) INDICATION High grade lymphoma. Omit rituximab if CD20 negative. PRE-ASSESSMENT 1. Ensure histology is confirmed prior to administration of chemotherapy and document in notes. 2. Record
More informationDiffuse Aggressive Lymphoma
Diffuse Aggressive Lymphoma Richard I. Fisher, Thomas P. Miller, and Owen A. O Connor The aggressive non-hodgkin s lymphomas can be cured in more than half of the cases. However, there has been great variation
More informationMARIO PETRINI Ematologia PISA UO Ematologia - Pisa
I LINFOMI NON HODGKIN A BASSO GRADO DI MALIGNITA PESCARA 2008 linfomi mantellari MARIO PETRINI Ematologia PISA Mantle Cell Lymphoma Typical (Classic) small to medium-sized Ly with scanty cytoplasm, irregular
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationLymphoma John P. Leonard, M.D.
Lymphoma 2017 John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department of Medicine Disclosures Consulting
More informationNIH Public Access Author Manuscript J Clin Oncol. Author manuscript; available in PMC 2008 June 3.
NIH Public Access Author Manuscript Published in final edited form as: J Clin Oncol. 2008 June 1; 26(16): 2717 2724. Phase II Study of Dose-Adjusted EPOCH-Rituximab in Untreated Diffuse Large B-cell Lymphoma
More information2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용
2018 KSMO Immune Oncology Forum Immune checkpoint inhibitors in hematologic malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018-07-18 Contents Introduction Immune checkpoint inhibtors in lymphomas
More informationAggressive B-cell lymphomas and gene expression profiling towards individualized therapy?
Aggressive B-cell lymphomas and gene expression profiling towards individualized therapy? Andreas Rosenwald Institute of Pathology, University of Würzburg, Germany Barcelona, June 18, 2010 NEW WHO CLASSIFICATION
More informationHow I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES
How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account
More informationChoice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma
Choice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationMathias J Rummel, MD, PhD
I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track
More informationDiffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationHow to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma
How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma Dr. Guillermo Rodríguez García Hospital Universitario Virgen Macarena Hospital Universitario Virgen del
More information*Jagiellonian University, Kraków, Poland
Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin s Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study Wojciech Jurczak, *
More informationNon-Hodgkin Lymphoma in Clinically Difficult Situations
Winship Cancer Institute of Emory University Non-Hodgkin Lymphoma in Clinically Difficult Situations James Armitage, MD Professor, Department of Internal Medicine Joe Shapiro Distinguished Chair of Oncology
More informationBiogen Idec Oncology Pipeline. Greg Reyes, MD, PhD SVP, Oncology Research & Development
Biogen Idec Oncology Pipeline Greg Reyes, MD, PhD SVP, Oncology Research & Development March 25, 2009 Biogen Idec Strategy in Lymphoma / Leukemia CLL RITUXAN NHL FC-RITUXAN GA101 RITUXAN-CVP RITUXAN-CHOP
More informationB Cell Lymphoma: Aggressive
B Cell Lymphoma: Aggressive UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Ibrutinib approved for mantle cell lymphoma as 2nd line therapy. - Aggressive lymphomas are a group of malignant
More informationLarge cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s
Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of
More informationState of the art: CAR-T cell therapy in lymphoma
State of the art: CAR-T cell therapy in lymphoma 14 th annual California Cancer Consortium conference Tanya Siddiqi, MD City of Hope Medical Center 8/11/18 Financial disclosures Consultant for Juno therapeutics
More informationManagement of high-risk diffuse large B cell lymphoma: case presentation
Management of high-risk diffuse large B cell lymphoma: case presentation Daniel J. Landsburg, MD Assistant Professor of Clinical Medicine Perelman School of Medicine University of Pennsylvania January
More informationNew agents for recurrent FL
Lymphoma and Myeloma 2015 Meeting New agents for recurrent FL Sven de Vos, MD, PhD Director, UCLA Lymphoma Program Los Angeles, CA Indolent Lymphoma Percent Survival Year 60 mos 120 mos 1944-54 29.3 17.2
More informationTransformed lymphoma: biology and treatment
Transformed lymphoma: biology and treatment Silvia Montoto Centre for Haemato-Oncology Barts Cancer Institute 1.00 0.75 0.50 0.25 0.00 N =330 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 Years %Viability
More informationTargeting Bruton s Tyrosine Kinase (BTK)
Targeting Bruton s Tyrosine Kinase (BTK) Lapo Alinari, MD, PhD 4 th International Conference, Translational Research in Oncology Forli, November 9-11/2016 The Ohio State University Comprehensive Cancer
More informationMantle Cell Lymphoma. A schizophrenic disease
23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving
More informationPharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765
Contact: Ramses Erdtmann Vice President of Finance Phone: 408-215-3325 Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765 Company to Host
More informationPolicy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide
More informationTARGETED THERAPY FOR CHILDHOOD CANCERS
TARGETED THERAPY FOR CHILDHOOD CANCERS AZIZA SHAD, MD AMEY DISTINGUISHED PROFESSOR OF PEDIATRIC HEMATOLOGY ONCOLOGY, BLOOD AND MARROW TRANSPLANTATION LOMBARDI CANCER CENTER GEORGETOWN UNIVERSITY HOSPITAL
More informationUpdates in T cell Lymphoma
Winship Cancer Institute of Emory University Updates in T cell Lymphoma Mary Jo Lechowicz August 2014 Objectives Update current care for patients with Peripheral T cell Non Hodgkin lymphomas (PTCL) upfront
More informationMEETING SUMMARY ASH 2018, San Diego, USA
MEETING SUMMARY ASH 2018, San Diego, USA Prof. Stefano Luminari University of Modena and Reggio Emilia, Italy AN UPDATE ON PROGNOSTIC FACTORS IN INDOLENT LYMPHOMAS 2 DISCLAIMER Please note: The views expressed
More informationPOST ICML Indolent lymphomas relapse treatment
POST ICML Indolent lymphomas relapse treatment Georg Hess University Medical School Johannes Gutenberg-University Mainz, Germany Treatment of relapsed indolent lymphoma 2 General categories of second line
More informationTARGETING EZH2 WITH TAZEMETOSTAT IN FOLLICULAR LYMPHOMA
TARGETING EZH2 WITH TAZEMETOSTAT IN FOLLICULAR LYMPHOMA VINCENT RIBRAG Chairman hematological multidisciplinary committee Ditep (chief molecular therapeutics in hematological early drug development) Bologna
More informationCPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults
MANAGEMENT IN CONFIDENCE CPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults The Benefits of the Proposition
More informationCarfilzomib for PTCL. Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center
Carfilzomib for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center jmvose@unmc.edu A spectrum of mutations observed in AITL target NF-κB pathway GEP: Enrichment of NF-κB Pathway in
More informationTRANSPARENCY COMMITTEE OPINION. 27 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 TORISEL 25 mg/ml, concentrate for solution and diluent for solution for infusion Box containing 1
More informationClinical Commissioning Policy Proposition: Bortezomib for relapsed/refractory mantle cell lymphoma
Clinical Commissioning Policy Proposition: Bortezomib for relapsed/refractory mantle cell lymphoma Reference: NHS England xxxxx 1 First published: TBC Prepared by NHS England Specialised Services Clinical
More informationSolomon Graf, MD February 22, 2013
Solomon Graf, MD February 22, 2013 Case Review of FL pathology, prognosis Grading of FL Grade 3 disease High proliferative index in grade 1/2 disease Pediatric FL Future of FL classification 57 yo man
More informationOverview of Lymphoma Clinical Trials
Overview of Lymphoma Clinical Trials Dr Pam McKay Beatson West of Scotland Cancer Centre Lymphoma Action Patient Conference September 2018 Clinical trials medical research involving human participants
More informationOverview. Table of Contents. A Canadian perspective provided by Isabelle Bence-Bruckler, MD, FRCPC
2 A C A N A D I A N P E R S P E C T I V E Volume 2 November 2005 Overview The International Conference on Malignant Lymphoma (ICML) is held every three years in Lugano, Switzerland. ICML started nearly
More informationB-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma
B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma May 2010 This technology summary is based on information available at the time of research and a limited literature search. It is
More informationMediastinal B-cell Lymphomas
Mediastinal B-cell Lymphomas A Spectrum of Diseases Wyndham H. Wilson, MD, PhD Mediastinal B-cell Lymphomas Nodular sclerosis Hodgkin Lymphoma Mediastinal grey zone lymphoma Primary mediastinal B-cell
More informationMANTLE CELL LYMPHOMA MTOR-INHIBITION
MANTLE CELL LYMPHOMA MTOR-INHIBITION Rome, 23. March 2017 Prof. Dr. med. Georg Heß III. Med. Klinik Universitäres Centrum für Tumorerkrankungen Universitätsmedizin der Johannes Gutenberg-Universität Mainz
More informationMantle cell lymphoma: The promise of new treatment options
Critical Reviews in Oncology/Hematology 80 (2011) 69 86 Mantle cell lymphoma: The promise of new treatment options Andre Goy a,, Brad Kahl b a Lymphoma Division, John Theurer Cancer Center, Hackensack
More informationWhat is the best approach to the initial therapy of PTCL? standards of treatment? Should all
What is the best approach to the initial therapy of PTCL? standards of treatment? hould all Jia Ruan, M.D., Ph.D. Center for Lymphoma and Myeloma Weill Cornell Medical College New York Presbyterian Hospital
More informationNHS England. Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma
NHS England Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma NHS England Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma
More informationChallenges in the Treatment of Follicular Lymphoma
Challenges in the Treatment of Follicular Lymphoma Prof. Michele Ghielmini Clinical Director Oncology Institute of Southern Switzerland Bellinzona ESMO guidelines 2014 (simplified) Low tumor burden High
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationDr. C. Tom Kouroukis. New and upcoming treatments for Lymphoma
Dr. C. Tom Kouroukis New and upcoming treatments for Lymphoma New and upcoming treatments for Lymphoma Dr. Tom Kouroukis Hamilton Convention Centre November 23, 2013 Overview Importance and design of clinical
More information